Skip to main content
Clinical Trials/IRCT20190917044805N2
IRCT20190917044805N2CompletedPhase 2

Effects of High-dose Vitamin C on Treatment, Clinical Symptoms and Laboratory Signs of Iranian COVID-19 Patients: A Double Blind Randomized Clinical Trial

Tehran University of Medical Sciences0 sites60 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
60

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to no limit (—)
Sex
All

Inclusion Criteria

  • Older than 18 years old
  • admission with moderate to severe COVID-19 based on WHO definition
  • Illness of any duration, and at least one of the following: Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), or Clinical assessment AND respiratory rate > 30 breaths/min; or severe respiratory distress; or SpO2 < 90% on room air.
  • Willing and be able to provide written informed consent prior to performing study procedures

Exclusion Criteria

  • Participation in any other clinical trial of an experimental treatment for COVID-19
  • Critical ill patients that need invasive mechanical ventilation
  • Stage 4 severe chronic kidney disease or requiring dialysis (i.e. eGFR < 30)
  • Patients with past medical history of kidney stone
  • Pregnancy or breastfeeding
  • Documented diagnosis of cancer?
  • History of G6PD deficiency ?and interstitial lung disease ?
  • More than 1 gram/day intake of vitamin C ?supplement in last 7 days

Investigators

Similar Trials